ReviewAesthetic surgery journal. Open forum2026
Incidence and Characteristics of Delayed Inflammatory Reactions Secondary to Hyaluronic Acid Filler Injections: A Systematic Review With Meta-Analysis.
Review in Aesthetic surgery journal. Open forum, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Delayed inflammatory reactions (DIRs) are rare but increasingly relevant complications of hyaluronic acid (HA) fillers. The aim of this review was to examine the incidence and characteristics of DIRs secondary to HA fillers for facial aesthetic indications. The authors systematically reviewed studies published before December 3, 2024, from PubMed and Embase, using a random-effects meta-analysis model to compute pooled incidence rates of DIR with 95% CIs. Subgroup analyses were performed according to filler crosslinking technology. Case data were analyzed descriptively. The meta-analysis included 242 studies, and case data were supplemented from 71 additional reports. The pooled incidence of DIRs was 0.0005 (95% CI, 0.0002-0.0013) events per patient-years, equivalent to an event occurring for every 2000 patients with 1 year of follow-up. When analyzed by crosslinking technology, incidence rates per patient-year were 0.0044 (95% CI, 0.0006-0.0314) for SHAPE (Stabilized Hyaluronic Acid And Purification Enhancement), 0.0022 (95% CI, 0.0011-0.0043) for Vycross, 0.0007 (95% CI, 0.0003-0.0017) for NASHA (Non-Animal Stabilized Hyaluronic Acid), and 0.0006 (95% CI, 0.0002-0.0025) for HICE (High Concentration Equalized); several filler technologies, including CPM (Cohesive Polydensified Matrix)-based fillers, reported no incident DIR cases during follow-up. The median time to onset was 3 months (range, 2 weeks to 12 years), and time to resolution was 2.9 months (range, 1 day to 6 years). Common presentations included nodules, redness, swelling, and induration. The management often involved hyaluronidase, corticosteroids, and antibiotics. DIRs are rare adverse events following aesthetic HA filler treatments, exhibiting varied times to onset and resolution. Incidence rates appear to vary by crosslinking technology, and awareness of potential differences can contribute to safe and natural outcomes.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.